Signatur Biosciences Ltd

Signatur Biosciences is developing OncoSignatur Breast (OSB), a decentralised, cost-effective breast cancer prognostic test that addresses the limitations of current centralised gene expression tests. OSB enables efficient local profiling of 21 genes predictive of chemotherapy benefit, eliminating overseas sample shipping. This reduces costs, accelerates turnaround times, and improves test accessibility. OSB provides healthcare systems with a decentralised solution for personalised care, helping thousands of women avoid unnecessary chemotherapy and its debilitating side effects. This grant will serve as a key catalyst for SigBio, advancing OSB from its prototype status to a fully developed, user-friendly kit.